Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea

Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO


SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).

Earlier on Friday,